Ovarian Cancer Drugs Market

Ovarian Cancer Drugs Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

248

Base Year:

2023

Apr - 2024

Format:

Report Code:

VMR-2462

Segments Covered

By Therapeutic Class PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors
By Treatment Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, Other Treatments
By End User Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2023
Forecast Years:	2024 - 2032
Historical Years:	2018 - 2022
Revenue 2023:	USD 3.7 Billion
Revenue 2032:	USD 6.67 Billion
Revenue CAGR (2024 - 2032):	6.8%
Fastest Growing Region (2024 - 2032)	Asia Pacific
Largest Region (2023):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. Global Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. Global Ovarian Cancer Drugs Market - by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. Global Ovarian Cancer Drugs Market - by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. Global Ovarian Cancer Drugs Market - by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. Global Ovarian Cancer Drugs Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
7. Market comparative analysis
North America Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. North America Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. North America Ovarian Cancer Drugs Market, by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. North America Ovarian Cancer Drugs Market, by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. North America Ovarian Cancer Drugs Market, by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. North America Ovarian Cancer Drugs Market, by Country
  1. U.S.
    1. U.S. Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. U.S. Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. U.S. Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  2. Canada
    1. Canada Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Canada Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Canada Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  3. Mexico
    1. Mexico Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Mexico Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Mexico Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
Europe Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. Europe Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. Europe Ovarian Cancer Drugs Market, by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. Europe Ovarian Cancer Drugs Market, by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. Europe Ovarian Cancer Drugs Market, by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. Europe Ovarian Cancer Drugs Market, by Country
  1. Germany
    1. Germany Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Germany Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Germany Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  2. UK
    1. UK Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. UK Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. UK Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  3. France
    1. France Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. France Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. France Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  4. Spain
    1. Spain Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Spain Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Spain Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  5. Italy
    1. Italy Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Italy Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Italy Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  6. BENELUX
    1. BENELUX Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. BENELUX Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. BENELUX Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  7. Rest of Europe
    1. Rest Of Europe Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Rest Of Europe Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Rest Of Europe Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
Asia Pacific Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. Asia Pacific Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. Asia Pacific Ovarian Cancer Drugs Market, by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. Asia Pacific Ovarian Cancer Drugs Market, by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. Asia Pacific Ovarian Cancer Drugs Market, by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. Asia Pacific Ovarian Cancer Drugs Market, by Country
  1. China
    1. China Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. China Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. China Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  2. Japan
    1. Japan Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Japan Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Japan Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  3. India
    1. India Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. India Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. India Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  4. South Korea
    1. South Korea Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. South Korea Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. South Korea Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  5. South East Asia
    1. South East Asia Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. South East Asia Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. South East Asia Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Rest of Asia Pacific Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Rest of Asia Pacific Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
Latin America Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. Latin America Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. Latin America Ovarian Cancer Drugs Market, by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. Latin America Ovarian Cancer Drugs Market, by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. Latin America Ovarian Cancer Drugs Market, by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. Latin America Ovarian Cancer Drugs Market, by Country
  1. Brazil
    1. Brazil Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Brazil Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Brazil Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  2. Argentina
    1. Argentina Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Argentina Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Argentina Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  3. Rest of Latin America
    1. Rest of Latin America Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Rest of Latin America Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Rest of Latin America Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
Middle East & Africa Ovarian Cancer Drugs Market - Segment Analysis
1. Overview
2. Middle East & Africa Ovarian Cancer Drugs Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Ovarian Cancer Drugs Market, by Therapeutic Class
  1. By PARP Inhibitors
  2. By Angiogenesis Inhibitors
  3. By PD-L1 Inhibitors
4. Middle East & Africa Ovarian Cancer Drugs Market, by Treatment
  1. By Chemotherapy
  2. By Radiation Therapy
  3. By Hormonal Therapy
  4. By Targeted Therapy
  5. By Other Treatments
5. Middle East & Africa Ovarian Cancer Drugs Market, by End User
  1. By Hospital Pharmacy
  2. By Retail Pharmacy
  3. By Online Pharmacy
6. Middle East & Africa Ovarian Cancer Drugs Market, by Country
  1. GCC Countries
    1. GCC Countries Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. GCC Countries Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. GCC Countries Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  2. South Africa
    1. South Africa Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. South Africa Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. South Africa Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Ovarian Cancer Drugs Market, By Therapeutic Class
      1. By PARP Inhibitors
      2. By Angiogenesis Inhibitors
      3. By PD-L1 Inhibitors
    2. Rest of Middle East & Africa Ovarian Cancer Drugs Market, By Treatment
      1. By Chemotherapy
      2. By Radiation Therapy
      3. By Hormonal Therapy
      4. By Targeted Therapy
      5. By Other Treatments
    3. Rest of Middle East & Africa Ovarian Cancer Drugs Market, By End User
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. F. Hoffmann-La Roche AG (Switzerland)
2. GlaxoSmithKline PLC (UK)
3. Immunogen Inc. (U.S.)
4. Astrazeneca (UK)
5. Merck KGaA (Germany)
6. Oasmia Pharmaceutical AB (Sweden)
7. Clovis Oncology Inc. (U.S.)
8. Novartis AG (Switzerland)
9. Bristol-Myers Squibb Company (U.S.)
10. Pfizer Inc. (U.S.)
11. Eli Lilly and Company (U.S.)
12. Aravive Biologics (U.S.)
13. Allarity Therapeutics (U.S.)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 20-May-2024

Novartis enhances oncology portfolio with deal to purchase MorphoSys AG at EUR 68 per share, totalling EUR 2.7 billion in cash

FAQ

Frequently Asked Question

What is the global demand for Ovarian Cancer Drugs in terms of revenue?

The global Ovarian Cancer Drugs valued at USD 3.7 Billion in 2023 and is expected to reach USD 6.67 Billion in 2032 growing at a CAGR of 6.8%.

Which are the prominent players in the market?

The prominent players in the market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (UK), Immunogen Inc. (U.S.), Astrazeneca (UK), Merck KGaA (Germany), Oasmia Pharmaceutical AB (Sweden), Clovis Oncology Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Aravive Biologics (U.S.), Allarity Therapeutics (U.S.).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 6.8% between 2024 and 2032.

What are the driving factors fueling the growth of the market.

The driving factors of the Ovarian Cancer Drugs include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Ovarian Cancer Drugs in 2023.

Ovarian Cancer Drugs Market

Ovarian Cancer Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Ovarian Cancer Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Ovarian Cancer Drugs Market

Ovarian Cancer Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Ovarian Cancer Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Ovarian Cancer Drugs Market

Vantage Point Interactive Dashboard